

February 27, 2023

For Private Circulation Only

	PREv CLOSe	OpeN	HiGh	LoW	CLOSe	Net CHNg (POINTs)	Net CHNg (%)
BSe SENSEx	59464	59331	59441	58938	59288	↓ -176	-0.30%
NSe NiFTy	17466	17429	17452	17299	17393	↓ -73	-0.42%
NIFTy MiDCAp 100	30103	30078	30082	29631	29895	↓ -209	-0.69%

D-STREET EXTENDS LOSING RUN To 7Th SESSIO...!!!

Indian shares fell with the benchmark indices slipping below a key long-term average intraday for the first time in over four months after US data reinforced fears of a prolonged high-interest rate regime and selling in auto, metal, information technology and capital goods names.

Bse Sector: Gainers: Realty, Bankex, Financial Services **Losers:** Teck, IT, Commodities, Telecommunication, Auto, Metal, Industrials, Capital Goods, Consumer Discretionary, Healthcare, FMCG, Services, Power, Energy, Consumer Durables, Utilities, Oil & Gas

ASIAN INDICES					EUROPEAN INDICES*				
CHINa	-0.28%	HONGKONG	-0.33%	JAPAn	-0.11%	FRANCe	1.66%	Uk	0.90%
SINGAPORE	-0.58%	S KOREa	-0.87%	TAIWAn	-0.71%	GERMANY	1.60%		

CBOe ViX (24-02-23)	US DOLLAR INDEX*
21.69	105.075

VENUs REMEDIEs LIMITED (##) : CMP Rs.164 (+2%)

Venus Remedies Limited has received good manufacturing practices (GMP) certification from Saudi Arabia for all its production facilities at its unit in Baddi, Himachal Pradesh. The Saudi Food and Drug Authority (SFDA) granted the certification, which included first-time approval for pre-filled Enoxaparin syringes and general injection facilities, and renewed approval for Cephalosporin and Carbapenem antibiotics and liquid and lyophilised oncology drugs, after an extensive review and audit of the company's facilities.

PVr LIMITEd : CMP Rs.1530 (-4%)

PVR Limited, the largest and the most premium cinema exhibition company in India, after the merger with INOX Leisure Limited announced the launch of a new 5-screen multiplex in the state of Telangana today. The new multiplex at Ashoka One Mall on Y Junction in Hyderabad will strengthen the company's foothold in Telangana with 102 screens in 18 properties and consolidates the merged entity's presence in South India with 508 screens in 92 properties. The multiplex is located in Kukatpally, a residential and commercial locality having excellent connectivity to the city's hotspots. Due to proximity to the IT hub of Hitech city and Gachibowli, Kukatpally has emerged as the preferred locality for professionals working in these IT hubs.

Dr. REDDY's LABORATORIEs LIMITEd (#) : CMP Rs.4415 (-2%)

Dr. Reddy's Labs SA, wholly-owned subsidiary of Dr. Reddy's Labs Ltd, announced that it has entered into a definitive agreement to acquire the U.S. generic prescription product portfolio of Salisbury, Australia, based Mayne Pharma Group Limited (ASX: MYX). The portfolio includes approx 45 commercial products, four pipeline products & 40 approved non-marketed products, including a number of generic products focused on women's health. Under the terms of the agreement, Dr. Reddy's will acquire the portfolio for an upfront payment of approx \$90 mn (USD) in cash, contingent payments of up to \$15 mn (USD), consideration towards inventory & credits for certain accrued channel liabilities to be determined on the closing date. The closing of the transaction is subject to satisfactory completion of customary closing conditions including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act), as amended.

GRANULEs INDIA LIMITEd : CMP Rs.281 (-2%)

Granules India Limited announced that the USFDA has approved its ANDA for Losartan Potassium Tablets USP, 25 mg, 50 mg, and 100 mg. It is bioequivalent to the reference listed drug product (RLD), Cozaar Tablets of Organon LLC. Granules now has a total of 54 ANDA approvals from US FDA (52 Final approvals and 2 tentative approvals). Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure.

BHARTi AIRTEI LIMITEd : CMP Rs.751 (-1%)

Bharti Airtel announced that it has crossed the 10 mn unique 5G user mark on its network. Airtel was the first service provider to roll-out 5G services in the country in Oct 2022. Today, Airtel 5G Plus is available across all states in the country. The company is well poised to cover every town and key rural areas with Airtel 5G services by end of Mar 2024. In Nov 2022, Airtel became the first and only operator to have 1 mn unique customers on its network within 30 days of its commercial launch.

BEATING tHe STREEt (Nifty): Gainers were ICICIBank, PowerGrid, KtkMah, SBI, HDFCLife, BPCL, NTPC, SBILifeIns, HDFC, AdaniPorts, AsianPaint
EXPECTATIOn BELIEd (Nifty): Losers were AdaniEntr, BajAuto, UPL, TataStl, Infy, EicherMtrs, TataMtrs, TCS, DivisLab, HeroM, MnM, DrReddys

MARKET BREADTh

ADVANCES	DECLINES	UNCHANGED	TOTAL
956 (26%)	2593 (69%)	186 (5%)	3735 (100%)

TURNOVER			CUM-DIV NSE 500				CUM- BASIS NSE 500		
	27-02-23	24-02-23	Company	EX DATE	27-02-23	Div	Company	EX DATE	ACTION
Bse	2577	5700	UJIVANSFB	01-03-23	26	0.75	SHAREINDIA	28-02-23	RIGHTS 1:50
Nse	40659	39791	HGS	06-03-23	1303	2.50	360ONE	02-03-23	BONUS 1:1
NSe FO	15412842	11470785					360ONE	02-03-23	FV SPLIT 2-1
NSe FPT**	57256	50462							

VOLUME SHOCKERs (Bse) (Shares IN LAKHs)

TATASTEEL	38.37	VEDL	10.84
RVNL	7.92	TATAPOWER	6.32

*Values recorded at the time of preparation of product * ** NSE F&O Premium Turnover

nishitass@sushilfinance.com

Additional information with respect to any securities referred to herein will be available upon request.

Sushil Financial Services Private Limited

Member : BSE / NSE - SEBI Regn. No. INZ000165135 | Research Analyst - SEBI Registration No. INH000000867

Tel.: 022-6698 0636 Fax: 022-6698 0606 E-mail: info@sushilfinance.com

Identification Suffixes: ## Fundamental Reports, # Universe, N.A (Data not available)

Please Note that our technical calls are totally independent of our fundamental calls.

Disclaimer & Disclosures:

<https://www.sushilfinance.com/Disclaimer/research>

<http://goo.gl/1sOHe>

This report has been furnished to you for your general information only and should not be reproduced, re-circulated, published in any media, website or otherwise, in any form or manner, in part or as a whole, without the express consent in writing of Sushil Financial Services Private Limited. This Research Report is meant solely for use by the original recipient to whom it is sent and is not for circulation. Any unauthorized use, disclosure or public dissemination or copying of information (either whole or partial) contained herein is prohibited.

This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice/offer for the purpose of purchase or sale of any securities mentioned herein. Past performance is not a guide for future performance, future returns are not guaranteed. Opinions expressed herein are subject to change without notice. Investor should rely on information/data arising out of their own investigations. The Sushil Equity Universe consists of ## Sushil's Classic - the company's where fundamental reports are published and # Sushil's Bonanza - the other company's under study.

Investors are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. The price and value of the investments referred to in this material and the income from them may go down as well as up, and investor may realize losses on any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by us to be reliable. A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com Research Analyst views on Subject Company may vary based on Fundamental and Technical Research. Sushil Financial Services Private Limited or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. None of the directors, employees, affiliates or representatives of company shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages/loss etc whatsoever from the information/opinions/views contained in this Report and investors are requested to use the information contained at their risk.

Sushil Financial Services Private Limited (SFSPL) and its connected companies, and their respective Directors, Officers and employees or their relative, may have a long or short position in the subject companies mentioned in the report and it may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Reports based on technical and derivative analysis centre on studying charts company's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamental analysis. SFSPL has different business segments/Divisions with independent research and maintains arm's length distance catering to different set of customers having various objectives, risk profiles, investment horizon, etc. and therefore may at times have different contrary views on stocks sector and markets. Research Report may differ between SFSPL's RAs on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold - SFSPL, its employees and associates responsible for any losses, damages of any type whatsoever.

This Report is not intended to be a complete statement or summary of the securities, market or developments referred to in this document. SFSPL or its affiliates or employees are under no obligation to update the information. SFSPL or its affiliates or employees shall not be in any way responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report.

SFSPL or its affiliates and/or its employees/its associates or his relative does not have financial interest in the subject companies. SFSPL or its affiliates and/ or its employees/its associates or his relative may or may not have beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report. SFSPL/its Associates/ Research Analyst have not received any compensation from the subject company in the past twelve months. Further the subject company is/was not a client during twelve months preceding the date of distribution of the research report and the types of services provided. SFSPL or its research analyst has not served as an officer, director or employee of the subject company. SFSPL or its affiliates and/or its research analysts have not been engaged in market making activity for the subject company. SFSPL or its associates or its Research Analyst have not received any compensation or other benefits from the subject companies or third party in connection with the research report. SFSPL/its Associates/ Research Analyst/ his Relatives not have any other material conflict of interest at the time of publication of the research report.

SFSPL/its Associates/ Research Analyst have not managed or co-managed public offering of securities, have not received compensation for investment banking or merchant banking or brokerage services, have not received any compensation for product or services other than investment banking or merchant banking or brokerage services from the subject companies in the last twelve months. There is no material disciplinary action that been taken by any regulatory authority impacting equity research analysis activities.

Additional information with respect to any securities referred to herein will be available upon request.

Sushil Financial Services Private Limited

Member : BSE / NSE - SEBI Regn. No. INZ000165135 | Research Analyst – SEBI Registration No. INH000000867

Tel.: 022-6698 0636 Fax: 022-6698 0606 E-mail: info@sushilfinance.com